Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
J&J’s ketamine-derived nasal spray approved by FDA to treat depression
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
NJBIZ8d
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
The FDA just approved this ketamine-derived nasal spray for depression treatment
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
US FDA approves standalone use of J&J’s ketamine-derived depression treatment
The US Food and Drug Administration (FDA) has expanded the approval for Johnson & Johnson’s nasal spray Spravato to allow its ...
Controlled drug Ketamine a lifeline for patients with severe depression in S’pore
Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
AOL7d
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
Johnson & Johnson, said in a news release. “For too long, health care providers have had few options to offer patients much-needed symptom improvement." The nasal spray was first approved by the ...
J&J's ketamine-based nasal spray Spravato approved by US FDA to treat depression
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...